Pharmacy is caught in a tangle of workforce burnout, vanishing storefronts, drug shortages, shifting regulations, and pricing battles that collectively threaten both the profession and the patients who depend on it. A systematic review pooling data from 17 studies found that roughly half of all pharmacists meet the criteria for burnout, and other pressures, from supply-chain fragility to the rise of artificial intelligence, are reshaping what pharmacists do and whether communities can access them at all.
Workforce Burnout and Staffing Shortages
The single issue pharmacists themselves talk about most is burnout. A pooled analysis across 17 studies estimated the overall burnout prevalence among pharmacists at about 51%, with risk factors including long hours, high prescription volumes, excessive workload, and poor work-life balance.1PubMed Central. A systematic review and pooled prevalence of burnout in pharmacists Community pharmacy settings appear to be hit especially hard. One U.S. survey found that roughly two-thirds of community-based pharmacists were experiencing burnout, with workload, lack of control over their schedules, and inadequate professional reward cited as the primary stressors.2PubMed Central. Burnout and Resilience in the Community-Based Pharmacist Practitioner
These numbers were already alarming before COVID-19, and the pandemic almost certainly made things worse. A narrative review of U.S. community pharmacist well-being noted that high burnout, low quality of life, and extreme fatigue predated the pandemic and have likely intensified since. The same review linked burnout to elevated rates of mental health disorders among pharmacists, reduced patient safety, and higher costs for employers and the broader healthcare system.3PubMed. A narrative review of the well-being and burnout of U.S. community pharmacists Staffing shortages feed the cycle: when burned-out pharmacists leave the profession, remaining staff absorb their workload, accelerating the next wave of departures.
Pharmacy Deserts and Store Closures
While pharmacists struggle inside the building, patients in many communities are losing the building altogether. A geospatial analysis published in 2025 found that about 57 million people in the contiguous United States live in pharmacy desert census tracts, and nearly 29 million rely on a single “keystone” pharmacy whose closure would leave them without a nearby option. Small rural areas are disproportionately affected, with about 14% of their residents depending on just one pharmacy.4JAMA Network Open. Vulnerability Index Approach to Identify Pharmacy Deserts and Keystone Pharmacies
The trend is getting worse. In 2022 and 2023, the three largest U.S. pharmacy chains announced plans to close more than 1,500 stores combined, and prior research shows that closures tend to cluster in low-income neighborhoods that are already pharmacy deserts.5PubMed Central. Locations and characteristics of pharmacy deserts in the United States: a geospatial study A spatial-economic analysis found that residents of medically underserved areas already travel almost twice as far to reach a pharmacy compared with people in better-served areas, and that pharmacy closures widen the gap further.6PLoS ONE. Rethinking access to care: A spatial-economic analysis of the potential impact of pharmacy closures in the United States For patients who depend on pharmacies not just for prescriptions but for vaccinations, blood-pressure checks, and basic health advice, a closure can mean a meaningful decline in access to care.
Drug Shortages and a Fragile Supply Chain
Chronic drug shortages have become one of pharmacy’s most persistent headaches, and the root causes are structural. An analysis in the Journal of Economic Perspectives argues that generic drug prices cannot easily adjust to market signals because of regulatory and contracting frictions, and that asymmetric information and agency problems in the U.S. market compound the difficulty.7Journal of Economic Perspectives. The Economics of Generic Drug Shortages: The Limits of Competition In other words, even when a shortage develops, the economic incentives for manufacturers to ramp up production are weak.
The geography of production makes everything more precarious. A systematic examination of generic active pharmaceutical ingredient (API) sources found that only about 14% of APIs for the U.S. market are manufactured domestically. India, China, and Italy are the top producers, and roughly a third of APIs come from a single facility worldwide, with another third from just two or three facilities.8Health Affairs. Competition And Vulnerabilities In The Global Supply Chain For US Generic Active Pharmaceutical Ingredients A disruption at one plant on the other side of the world can empty shelves at your local pharmacy for months. For pharmacists on the front line, managing these shortages means hours spent contacting wholesalers, calling prescribers to suggest alternatives, and explaining delays to frustrated patients.
Expanding Scope of Practice
Against the backdrop of burnout and closures, a counter-trend is pushing pharmacists into a larger clinical role. Several states now allow pharmacists to prescribe certain medications directly, bypassing the traditional requirement for a physician’s prescription. A recent study found that granting pharmacists prescribing authority for pre-exposure prophylaxis (PrEP), the HIV-prevention medication, increased PrEP prescription rates by about 12%. The biggest gains came in states that did not require pharmacists to complete additional mandatory training, suggesting that bureaucratic requirements can blunt the benefit of expanded scope.9PubMed Central. Expanding Pharmacists’ Prescribing Authority and Medication Uptake: Evidence From Pre-Exposure Prophylaxis
Hormonal contraception is another frontier. A growing number of U.S. jurisdictions now let pharmacists prescribe birth control, though most require additional training beyond the standard pharmacy degree.10PubMed Central. Through the Lens of Expanded Scope of Practice: Training Requirements for Pharmacist-Prescribed Contraception Across the United States These expanded authorities can help close access gaps, especially in rural areas, but they also add complexity. Pharmacists are being asked to do more, often without corresponding increases in staffing or pay, which loops right back into the burnout problem.
Drug Pricing, Biosimilars, and the Inflation Reduction Act
The cost of medications remains one of the most politically charged issues in American healthcare, and pharmacies sit at the center of it. Specialty pharmaceuticals, the high-cost medications used for complex or chronic conditions, have been growing in expense for years and now dominate pharmacy spending.11PubMed Central. A review of approaches for the management of specialty pharmaceuticals in the United States Biosimilars were supposed to bring some relief by providing lower-cost alternatives to brand-name biologics, much as generics did for traditional drugs. But adoption has been slow.
State substitution laws are one obstacle. A study of insulin glargine-yfgn, the first interchangeable insulin biosimilar, found that its market share rose significantly faster in states with less restrictive substitution laws. In states that required enhanced physician notification or patient notification before a pharmacist could make the switch, uptake was meaningfully lower.12PubMed Central. State Substitution Laws and Uptake of an Interchangeable Insulin Biosimilar Beyond state law, systemic factors like anticompetitive patent practices, pharmacy benefit manager (PBM) incentives, and Medicare reimbursement structures continue to favor brand-name biologics over cheaper biosimilar alternatives.13PubMed. Breaking Barriers: Essential Reforms for a Competitive and Affordable Biosimilars Market
The Inflation Reduction Act (IRA), which gave Medicare the authority to negotiate drug prices directly, is generating its own pharmacy-level complications. An analysis of its impact on long-term care pharmacies estimated that the shift to negotiated “maximum fair prices,” combined with inadequate dispensing fees, could slash revenue by more than 85% for the specific drugs selected for negotiation.14PubMed Central. Challenges of the Inflation Reduction Act for long-term care pharmacy: Examining impact and policy solutions There is also concern that PBMs, facing squeezed margins on negotiated drugs, may respond by raising out-of-pocket costs for seniors on other medications, increasing utilization management hurdles, or further cutting pharmacy reimbursement.15PubMed Central. Could the Inflation Reduction Act Maximum Fair Price Hurt Patients? The law’s goals are popular, but the downstream effects on pharmacy economics are still playing out.
Controlled Substances and the Opioid Crisis
Pharmacists occupy an uncomfortable position in the opioid epidemic. They are legally and ethically responsible for ensuring that controlled substances are dispensed appropriately, which sometimes means refusing to fill a prescription. That decision is never simple. Research into how community pharmacists handle these refusals found that the process involves balancing professional judgment, regulatory obligations, and patient-centered care, including verifying prescriptions, seeking external guidance, and documenting interactions.16Journal of the American Pharmacists Association. It’s not in stock: Community pharmacists’ decision-making and communication when refusing to dispense controlled substance prescriptions Pharmacists are expected to identify “red flag” behaviors that suggest misuse, use prescription drug monitoring programs, educate patients on safe storage and disposal, and know when to refer someone to addiction services.17PubMed. The Role of Pharmacists in Safe Opioid Dispensing
At the same time, the profession is being asked to provide harm reduction services like naloxone distribution and syringe access. Although most pharmacies now stock naloxone and sell non-prescription syringes, store policies and pharmacists’ personal beliefs still create barriers.18PubMed Central. Pharmacist attitudes and provision of harm reduction services in North Carolina: an exploratory study Training programs designed to reduce stigma toward people with substance use disorder have shown some success in changing pharmacist attitudes, but they have been less effective at overcoming the structural challenges pharmacists face in providing these services day to day.19PubMed Central. “I go out of my way to give them an extra smile now:” A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials
Technology, AI, and Alert Fatigue
Artificial intelligence is beginning to reshape pharmacy practice. A systematic review found that AI tools are already being used for detecting adverse drug events, supporting clinical decisions, verifying prescription accuracy, and predicting how individual patients will respond to specific therapies.20PubMed Central. Artificial intelligence in clinical pharmacy—A systematic review of current scenario and future perspectives In one practical application, an AI-powered comprehensive medication management program combined population health data with telemedicine to identify high-risk patients. When clinical pharmacists worked alongside this system, the result was lower healthcare spending and fewer emergency department visits and hospital admissions.21Exploratory Research in Clinical and Social Pharmacy. Artificial intelligence in the field of pharmacy practice: A literature review
But technology is not purely helpful. Drug utilization review systems in electronic health records are a case in point. These systems generate safety alerts whenever a pharmacist processes a prescription, flagging potential interactions and dosing concerns. The problem is that the vast majority of these alerts are low-level and clinically irrelevant, making it hard to spot the ones that actually matter. The result is alert fatigue, a well-documented phenomenon that contributes to burnout and, paradoxically, can threaten patient safety by desensitizing the very professionals the alerts are supposed to protect.22PubMed Central. Pharmacists’ Perceptions on Safety Alerts of the Drug Utilization Review (DUR) in Electronic Health Records in a Tertiary Healthcare Hospital
Direct-to-Consumer Pharmacies and Compounding Concerns
Online direct-to-consumer (DTC) pharmacies, brands like Cost Plus Drugs, Amazon Pharmacy, and others, have attracted attention for offering generic medications at steep discounts. A cross-sectional analysis found that for the most expensive generics available through DTC pharmacies, median savings were about $231 per drug, or roughly 76%, compared with traditional retail prices. Common, less expensive generics were widely available too, though the dollar savings were more modest. The catch is that many of the most expensive generic drugs are not available at DTC pharmacies at all, meaning patients with complex medication regimens may still need a traditional pharmacy.23PubMed Central. Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer Pharmacies
Compounding pharmacies present a different set of concerns, especially in the context of the GLP-1 weight-loss drug boom. A pharmacovigilance study using FDA adverse event data found that compounded versions of GLP-1 receptor agonists had dramatically higher rates of preparation errors, contamination issues, and compounding and manufacturing problems compared with commercially manufactured versions. Hospitalization odds were also more than twice as high for patients taking compounded products.24PubMed. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system As demand for these medications surges and patients seek cheaper alternatives, the safety gap between regulated and compounded products is a growing regulatory headache.
Pharmacogenomics in Practice
Pharmacogenomics, the idea that a person’s genetic makeup can predict which drugs will work best for them and which might cause harmful side effects, has been a concept in pharmacy education for years. Translating it into routine community pharmacy practice has been slow. A scoping review of community pharmacy implementation found that while pharmacists generally view pharmacogenomic testing positively and see it as fitting within their professional role, they also report significant barriers: gaps in their own knowledge, low confidence in interpreting and communicating results, worries about cost, and concerns about patient privacy.25Journal of the American Pharmacists Association. Pharmacogenetic testing in community pharmacies: A scoping review of implementation approaches, outcomes, and factors affecting uptake
Expert opinion leaders in the field echo some of these themes. In a cross-sectional survey, the most frequently cited barriers were cost, inadequate technology infrastructure to integrate genetic data into pharmacy workflows, and legal or regulatory uncertainty about how the information should be handled.26PubMed Central. Barriers, facilitators, and implementation strategies for pharmacogenomics in community pharmacies: a cross-sectional survey among local champions in pharmacies and key opinion leaders in pharmacogenomics Until electronic health records can seamlessly display genetic results at the point of dispensing, and until reimbursement models catch up, pharmacogenomics will likely remain a niche service rather than a standard part of care.
The Pharmacy Education Pipeline
Underlying many of these issues is a quieter crisis in the educational pipeline feeding the profession. Applications to U.S. pharmacy schools have been declining since 2013, creating what one analysis described as “survival-of-the-fittest conditions” among programs. Some schools are struggling to fill their incoming classes, and the viability of multiple programs is under threat.27PubMed Central. Years of Rampant Expansion Have Imposed Darwinian Survival-of-the-Fittest Conditions on US Pharmacy Schools A separate commentary noted that shifting demographics, the transition to a knowledge-based economy, and rapid technological change are all compounding the challenge, and urged the academy to focus on student retention and redesigning educational models rather than simply trying to recruit more applicants.28American Journal of Pharmaceutical Education. Challenges and Opportunities for Pharmacy Education: Admissions, Retention, Curriculum, and Workforce Demands
If fewer talented students enter pharmacy programs, and if those programs do not evolve to prepare graduates for expanded clinical roles, the profession will struggle to meet the demands being placed on it. The irony is hard to miss: pharmacy is being asked to do more than ever, at a moment when fewer people want to become pharmacists.
Pharmaceutical Waste and Counterfeit Medications
Two issues that rarely make headlines but carry serious long-term consequences are pharmaceutical waste and counterfeit drugs. The global increase in pharmaceutical production and consumption has led to a surge in pharmaceutical waste, and improper disposal methods contribute to disruptions in aquatic ecosystems and the spread of antimicrobial resistance.29PubMed. Environmental and Health Consequences of Pharmaceutical Disposal Methods: A Scoping Review Pharmacies are increasingly involved in drug take-back programs, but the infrastructure for safe collection and disposal is still patchy.
Counterfeit medications are a parallel threat. Internet pharmacies, which sometimes misrepresent their origin to gain consumer trust, are a common channel for counterfeit products. Beyond the financial harm to consumers and manufacturers, counterfeit drugs pose direct health hazards, including the possibility of death, because they may contain the wrong active ingredient, the wrong dose, or dangerous contaminants.30PubMed Central. The health and economic effects of counterfeit drugs As more patients shop online to save money, the risk of encountering substandard or fake products grows, placing an additional burden on regulators and legitimate pharmacies to educate the public.